Abstract: The present invention concerns the use of a sphingoid-polyalkylamine conjugate as a capturing agent of biologically active molecules, such as antigens. In a particular embodiment, the spinogid-polyalkylamines are used for the preparation of pharmaceutical composition for stimulating or enhancing an immune response of a subject to protect against Hepatitis B Virus (HBV) infection. Other aspects of the invention concern methods for stimulating or enhancing an immune response of a subject to protect against Hepatitis B Virus (HBV) infection, by the use of the sphingoid-polyalkylamine conjugate, complexes comprising the sphingoid-polyalkylamine conjugate and a biologically active molecule, the latter, having an effect of stimulating or enhancing an immune response of a subject against to protect Hepatitis B Virus (HBV) infection, as well as kits making use of said conjugates and complexes. A preferred conjugate according to the invention is N-palmitoyl D-erythro sphingosyl-1-carbamoyl spermine (CCS).
Type:
Grant
Filed:
February 2, 2006
Date of Patent:
March 15, 2011
Assignees:
Yissum Research Development Company of the Hebrew University of Jersusalem, Biolab Ltd., Nasvax Ltd.
Abstract: The present disclosure provides processes for the preparation of lipid conjugated cyclic carbonate derivatives. More specifically, the present disclosure is based on the finding that reacting lipids, such as, ceramides, with N,N?-disuccinimidyl derivative, resulted in the formation of, isolatable, substituted cyclic [1,3]-dioxan-2-one and [1,3]-dioxan-2-thione compounds. These isolatable cyclic substituted compounds and derivatives thereof may be used for various applications, such as in vaccination.
Type:
Application
Filed:
May 11, 2008
Publication date:
December 2, 2010
Applicants:
BIOLAB LTD., NASVAX LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
Abstract: The present application discloses methods for stimulating or enhancing an immune response of a subject to protect against an infection caused by an agent selected from Hepatitis B Virus (HBV), avian influenza virus, the bacterium Bacillus anthracis or the bacterium Streptococcus pneumoniae, the method comprising administering to said subject a combination of sphingoid-polyalkylamine conjugate and a biologically active molecule, the combination being effective to provide said stimulation or enhancement of the immune response. Also disclosed are vaccines comprising a combination of the sphingoid-polyalkylamine conjugate and a biologically active molecule for stimulating or enhancing an immune response of a subject to protect against an infection caused by such an agent. Preferred conjugates are N-palmitoyl D-erythro sphingosyl-1-carbamoyl spermine (C-1 CCS), N-palmitoyl D-erythro sphingosyl-3-carbamoyl spermine (C-3 CCS) and mixtures thereof. Also disclosed are uses of C-3 CCS for various applications.
Type:
Application
Filed:
May 9, 2007
Publication date:
November 15, 2007
Applicants:
Yissum Research Development Company of the Hebrew University of Jerusalem, BioLab Ltd., NasVax Ltd.
Abstract: The present invention concerns the use of a sphingoid-polyalkylamine conjugate as a capturing agent of biologically active molecules, such as antigens. In a particular embodiment, the spinogid-polyalkylamines are used for the preparation of pharmaceutical composition for stimulating or enhancing an immune response of a subject to protect against Hepatitis B Virus (HBV) infection. Other aspects of the invention concern methods for stimulating or enhancing an immune response of a subject to protect against Hepatitis B Virus (HBV) infection, by the use of the sphingoid-polyalkylamine conjugate, complexes comprising the sphingoid-polyalkylamine conjugate and a biologically active molecule, the latter, having an effect of stimulating or enhancing an immune response of a subject against to protect Hepatitis B Virus (HBV) infection, as well as kits making use of said conjugates and complexes. A preferred conjugate according to the invention is N-palmitoyl D-erythro sphingosyl-1-carbamoyl spermine (CCS).
Type:
Application
Filed:
February 2, 2006
Publication date:
August 3, 2006
Applicants:
Yissum Research Development Company of the Hebrew University of Jerusalem, BIOLAB LTD., NasVax Ltd.